Rymo Technologies Raises ₹10 Crore in Seed Funding Led by IAN Angel Fund to Expand Neuro-Rehab Access

IAN Group, the country’s single largest early-stage investment platform, has invested in Rymo Technologies, a robotic neuro-rehabilitation startup, in its seed funding round of over INR 10 crore, through its evergreen fund, IAN Angel Fund, with participation from other angel investors.

The fresh capital will be used to accelerate product innovation, expand manufacturing capabilities, and strengthen the company’s presence across India while scaling into international markets, including ASEAN and the Middle East.

Founded by Chirag Shah (CEO) and Abhishek Rai (CTO), Rymo Technologies is working to address a structural gap in neuro-rehabilitation. While the incidence of stroke and neurological disorders continues to rise globally, access to advanced rehabilitation remains limited due to a shortage of trained therapists and the high cost of robotic rehabilitation systems. As a result, patients in Tier 1/2 cities and smaller hospitals often lack access to advanced therapy solutions.

For IAN, the opportunity lies not only in the growing demand for rehabilitation technology but also in the company’s ability to address this gap with a scalable and validated solution.

The company has already demonstrated strong traction across the healthcare ecosystem, with more than 452 device installations and 354 clinical customers, including leading institutions such as AIIMS, Apollo Hospitals, and Manipal Hospitals. Rymo’s systems have supported over 7,500 patients, delivering more than 15,000 therapy hours, with studies indicating up to 25% faster recovery outcomes.

Chirag Shah, Co-founder & CEO, Rymo Technologies, said, “Our goal is to democratize world-class rehabilitation so that no patient is left behind due to cost or infrastructure barriers. With this financing, we hope to grow internationally, develop our technology, and give more patients and healthcare professionals access to superior robotic rehabilitation.”

Rymo’s approach focuses on bringing robotic and AI-assisted rehabilitation technology to mid-sized hospitals and physiotherapy clinics at an accessible price point, enabling healthcare providers beyond large metropolitan hospitals to offer advanced rehabilitation services.

Beyond clinical adoption, the company has built a multi-layered technology foundation that combines patented hardware architecture, proprietary algorithms trained on patient data, and modular system design. At the core of the platform is a multi-joint robotic rehabilitation system being integrated with AI-driven therapy personalization designed to deliver measurable recovery outcomes. These capabilities, along with regulatory progress and international clinical validation studies, including one currently underway in Italy, create a strong platform for global expansion.

Rymo’s price-performance advantage also positions it uniquely in the market. While global robotic rehabilitation systems can cost several times more, Rymo’s solutions are designed to make advanced rehabilitation accessible to Tier 1/2 clinics, mid-sized hospitals, and emerging healthcare markets that have historically been unable to adopt such technology.

The company has also made progress on regulatory and international expansion fronts. Rymo has received US FDA classification as a Class II medical device and has signed a distribution partnership with Fourier Rehab to expand into ASEAN markets.

The global neuro-rehabilitation devices market, valued at approximately $2.16 billion and growing at around 14%annually, presents a significant opportunity, particularly as healthcare systems seek scalable rehabilitation solutions for rising neurological disorders.

Rymo aims to capture this opportunity by building a connected neuro-rehabilitation ecosystem leveraging robotics, the Internet of Things, virtual reality and other advanced technologies.